The medical sector is usually of interest during economic uncertainty, especially when it leads to heightened stock market volatility.With investors feeling the jitters from tariff concerns and rising geopolitical tensions, several healthcare stocks have made their way onto the coveted Zacks Rank #1 (Strong Buy) list.  Jazz Pharmaceuticals – JAZZ  Standing out in terms of value, Jazz Pharmaceuticals' (JAZZ)  robust earnings are hard to ignore as a specialty biopharmaceutical company focusing on neuroscience ...

Investors might want to bet on Jazz Pharmaceuticals (JAZZ) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this drugmaker, should get reflected in its stock price. After all, empirical research shows a strong correlation betwe ...

Shares of Jazz Pharmaceuticals (JAZZ) have gained 15.4% over the past four weeks to close the last trading session at $143.53, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $186.06 indicates a potential upside of 29.6%.The average comprises 18 short-term price targets ranging from a low of $128 to a high of $230, with a standard deviation of $26.62. While the lowest estimate i ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style S ...

Core Insights - Jazz Pharmaceuticals reported total revenue of $1.09 billion for the quarter ending December 2024, reflecting a year-over-year increase of 7.5% [4] - The analysis of international revenue streams is crucial for understanding the company's financial health and growth potential [2][3] International Revenue Breakdown - Revenue from "All other regions" was $32.67 million, accounting for 3.00% of total revenue, which was a surprise increase of 37.02% compared to the expected $23.84 million [5] - Europe generated $81.89 million, representing 7.53% of total revenue, slightly exceeding the projected $81.04 million by 1.04% [6] - The previous quarter's contributions from Europe were $77.32 million (7.33%) and from "All other regions" were $23.98 million (2.27%) [5][6] Future Revenue Expectations - Analysts predict total revenue of $984.6 million for the current fiscal quarter, indicating a 9.2% increase from the prior year [7] - Expected contributions from "All other regions" and Europe for the current quarter are $20.48 million (2.1%) and $72.96 million (7.4%), respectively [7] - For the full year, total revenue is anticipated to reach $4.3 billion, up 5.6% from the previous year, with "All other regions" and Europe expected to contribute $90.67 million (2.1%) and $322.05 million (7.5%) [8] Strategic Considerations - The reliance on international markets presents both opportunities and challenges for Jazz Pharmaceuticals, making the tracking of international revenue trends essential for future projections [9] - The interconnectedness of global economies and geopolitical factors necessitates close monitoring of international revenue trends by analysts [10]

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.He leads the investing group Growth Stock Forum which features: a model portfolio of 15-2 ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style Sco ...

Jazz Pharmaceuticals (JAZZ) reported fourth-quarter 2024 adjusted earnings of $6.60 per share, which beat the Zacks Consensus Estimate of $5.79. Earnings rose 31% year over year.Total revenues rose 8% year over year to $1.09 billion. Sales of Xywav and Epidiolex drove this upside. The reported figure beat the Zacks Consensus Estimate of $1.06 billion.See the Zacks Earnings Calendar to stay ahead of market-making news.Shares of Jazz rose more than 2% in pre-market today, likely due to the better-than-expecte ...

Product Development and Pipeline - The company reported approximately 14,150 patients taking Xywav by the end of 2024, including about 10,250 patients with narcolepsy and approximately 3,900 patients with idiopathic hypersomnia (IH) [417]. - Xywav is recognized as the first and only FDA-approved therapy for the treatment of IH in adults, with seven years of orphan drug exclusivity extending through August 2028 [415]. - The company acquired Epidiolex in May 2021, expanding its neuroscience business with a high-growth childhood-onset epilepsy franchise [418]. - Rylaze was launched in the U.S. in July 2021 and is the only recombinant erwinia asparaginase product approved in the U.S. [419]. - The company focuses on research and development activities within neuroscience and oncology therapeutic areas to drive sustainable growth [408]. - The company aims to identify and develop differentiated therapies for patient populations with high unmet needs [407]. - The company continues to expand its pipeline to achieve a valuable portfolio of durable, highly differentiated products [410]. - Zepzelca was launched in the U.S. in early 2020 for treating SCLC patients after platinum-based chemotherapy, with ongoing promotional efforts targeting SCLC-treating physicians [420]. - A Phase 3 trial in collaboration with Roche for Zepzelca and Tecentriq showed statistically significant benefits, with plans for an sNDA submission in the first half of 2025 [420]. - Zanidatamab received FDA approval in November 2024 for second-line HER2-positive BTC, with a total potential payment to Zymeworks of $1.76 billion under the licensing agreement [427]. - The ongoing Phase 3 trials for zanidatamab include first-line HER2-positive GEA and BTC, with additional trials for previously treated HER2-positive breast cancer [436]. - JZP441, an orexin-2 receptor agonist, achieved initial proof-of-concept in a Phase 1 trial, with plans for a Phase 1b trial in narcolepsy Type 1 patients in 2025 [435]. - The company has multiple ongoing clinical trials for zanidatamab, including a pivotal Phase 2 trial for advanced HER2-amplified BTC, with a BLA submission completed in March 2024 [427]. - The company is exploring options for the suvecaltamide program after recent trials did not achieve statistical significance on primary endpoints [434]. Financial Performance - Product sales, net for 2024 reached $3,821,164, a 2% increase from 2023's $3,736,943, which was a 3% increase from 2022's $3,641,429 [454]. - Royalties and contract revenues surged to $247,786 in 2024, a 155% increase from $97,261 in 2023, which was a 442% increase from $17,945 in 2022 [454]. - Xywav product sales increased by 16% in 2024 to $1,473,202, driven by an 8% increase in patients taking the drug for narcolepsy and a 41% increase for idiopathic hypersomnia (IH) compared to 2023 [458]. - Xyrem product sales decreased by 59% in 2024 to $233,816, primarily due to competition from high-sodium oxybate and the adoption of Xywav [455]. - Research and development expenses rose to $884,000 in 2024, a 4% increase from $849,658 in 2023, with clinical studies and outside services costs contributing significantly [467]. - Selling, general and administrative expenses increased to $1,385,294 in 2024, a 3% increase from $1,343,105 in 2023, driven by higher compensation-related expenses and increased investment in sales and marketing [464]. - The gross margin as a percentage of net product sales was 88.3% in both 2024 and 2023, compared to 85.2% in 2022 [462]. - The company expects product sales to increase in 2025, primarily driven by growth across its commercial portfolio, despite a decrease in Xyrem sales due to competition [460]. - The company anticipates royalties and contract revenues to increase in 2025, primarily due to higher royalty revenues from high-sodium oxybate AG sales [461]. - Research and development expenses are expected to decrease in 2025 compared to 2024, mainly due to reduced costs related to clinical studies [468]. Competition and Market Dynamics - Xywav faces competition from Avadel's Lumryz, which was launched in June 2023, and the company has filed a complaint against the FDA regarding Lumryz's approval [442]. - The launch of authorized generic (AG) versions of high-sodium oxybate has negatively impacted Xyrem and Xywav sales, with Hikma and Amneal launching their AG products in January and July 2023, respectively [443]. - Lupin received tentative approval for a generic version of Xywav on October 13, 2023, indicating increasing generic competition [444]. - The commercial success of Epidiolex/Epidyolex is uncertain due to potential competition from generic products and non-FDA approved alternatives [446]. Shareholder Returns and Capital Management - The company announced a new share repurchase program authorized for up to $500 million, replacing the previous program which had an authorized repurchase amount of $1.5 billion [2]. - The company repurchased 2.8 million ordinary shares for $311.4 million in 2024, with an average purchase price of $110.06 per share [483]. - The New Repurchase Program authorized in July 2024 allows for ongoing share repurchases without an expiration date [483]. Debt and Financing - The principal amount of Tranche B-1 and B-2 Dollar Term Loans each totaled $2.7 billion [491]. - The applicable margin for Tranche B-2 Dollar Term Loans is 2.25% for Term SOFR borrowings, a decrease of 75 basis points from Tranche B-1 [492]. - As of December 31, 2024, the interest rate on Tranche B-2 Dollar Term Loans was 6.61% and the effective interest rate was 8.27% [492]. - The Initial Revolving Credit Facility was increased from $500.0 million to $885.0 million [493]. - Interest on the 2030 Notes is payable at a rate of 3.125% per year, maturing on September 15, 2030 [504]. - The 2026 Notes have an interest rate of 2.00% per year and mature on June 15, 2026 [509]. - The 2024 Notes were repaid in full on August 15, 2024, totaling $575.0 million [513]. - The interest rate on the Secured Notes was 4.375% as of December 31, 2024 [502]. - The Amended Revolving Credit Facility has a commitment fee ranging from 0.25% to 0.45% per annum based on the first lien secured net leverage ratio [495]. Tax and Regulatory Considerations - Income tax benefit was $91.4 million in 2024, down from $119.9 million in 2023 and $158.6 million in 2022, primarily due to changes in income mix across jurisdictions [475]. - Regulatory scrutiny and potential healthcare reforms may impact pricing and reimbursement for the company's products, affecting overall revenue [450]. Cash Flow and Investments - Cash flows from operations were $1.4 billion in 2024, an increase of $303.9 million compared to $1.1 billion in 2023 [484]. - Net cash used in investing activities increased by $345.1 million in 2024 compared to 2023, driven by a $340.0 million net increase in the acquisition of investments [487]. - The company plans to commit substantial resources to product acquisition, development, and expansion of operations [481]. Goodwill and Intangible Assets - As of December 31, 2024, the company had $1.7 billion of goodwill resulting from acquisitions accounted for as business combinations [531]. - The fair value of the reporting unit significantly exceeded its carrying amount, indicating no impairment of goodwill as of the annual test in October 2024 [531]. - The company expects to continue acquiring intangible assets, with fair values determined using discounted cash flow models [533]. - As of December 31, 2024, the company had $4.8 billion of finite-lived intangible assets, including $3.3 billion related to Epidiolex and $1.0 billion related to Vyxeos [537]. - No impairment charge was recognized for intangible assets in 2024 or 2023; however, a $133.6 million impairment charge was recorded in 2022 for the nabiximols program [538]. Foreign Exchange and Interest Rate Management - A hypothetical 10% strengthening or weakening in exchange rates would have increased or decreased net income by approximately $78.0 million for sterling and $3.3 million for euro [553]. - As of December 31, 2024, the net liability fair value of outstanding foreign exchange forward contracts was $7.9 million, with notional amounts totaling $461.2 million [554]. - The company entered into interest rate swap agreements with a notional amount of $500.0 million, fixing the interest rate on a portion of term loan borrowings at 3.9086% until April 30, 2026 [550]. - The fair values of the 2030 Notes, Secured Notes, and 2026 Notes were estimated to be $1.1 billion, $1.4 billion, and $1.0 billion, respectively, as of December 31, 2024 [552]. Tax Jurisdictions - The company has significant operations in Ireland, the U.K., and the U.S., which are its most significant tax jurisdictions [541].

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Jeff Macdonald - Executive Director, Investor Relations Bruce Cozadd - Co-Founder, Chairman and Chief Executive Officer Renée Galá - President and Chief Operating Officer Robert Iannone - Executive Vice President, Global Head, Research and Development, Chief Medical Officer Philip Johnson - Executive Vice President and Chief Financial Officer Conference Call Participants Marc Goodman - L ...